{"id":"NCT04338321","sponsor":"Janssen-Cilag International NV","briefTitle":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","officialTitle":"A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-21","primaryCompletion":"2022-01-20","completion":"2022-07-15","firstPosted":"2020-04-08","resultsPosted":"2023-02-15","lastUpdate":"2025-04-29"},"enrollment":676,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Esketamine 28 mg","otherNames":[]},{"type":"DRUG","name":"Esketamine 56 mg","otherNames":[]},{"type":"DRUG","name":"Esketamine 84 mg","otherNames":[]},{"type":"DRUG","name":"Quetiapine XR 50 mg","otherNames":[]},{"type":"DRUG","name":"Quetiapine XR 100 mg","otherNames":[]},{"type":"DRUG","name":"Quetiapine XR 150 mg","otherNames":[]},{"type":"DRUG","name":"SSRI/SNRI","otherNames":[]}],"arms":[{"label":"Esketamine Arm","type":"EXPERIMENTAL"},{"label":"Comparator Arm","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission in participants who have treatment-resistant major depressive disorder (MDD) with a current moderate to severe depressive episode.","primaryOutcome":{"measure":"Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Esketamine Nasal Spray + Oral Antidepressant (AD)","deltaMin":27.1,"sd":null},{"arm":"Quetiapine Extended Release (XR) + Oral AD","deltaMin":17.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":171,"countries":["Argentina","Austria","Belgium","Brazil","Bulgaria","Czechia","Denmark","Finland","Germany","Greece","Hungary","Israel","Kazakhstan","Malaysia","Netherlands","Norway","Poland","Portugal","South Africa","South Korea","Sweden","Taiwan","Turkey (TÃ¼rkiye)","United Arab Emirates"]},"refs":{"pmids":["38169503","38169502","37792613"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":334},"commonTop":["Dizziness","Somnolence","Headache","Nausea","Dissociation"]}}